Although few inhibitors have been recently investigated in in vitro / in vivo settings [81] (most inhibiting the eraser FTO [82]), and despite a very recent and remarkable report of a METTL3 inhibitor with anti-cancer properties documented in myeloid leukemia [83], most inhibitors are rather non-selective and have limited target potency. Here, FTO is linked to myeloid leukemia.